Combimist L Inhaler
Designed to support bronchodilation to manage obstructive airway episodes and alleviate physical breathing distress.
- Category
- Respiratory Health
- Active ingredients
- Levosalbutamol · Ipratropium
- Route
- Inhalation use
- Form
- Inhaler
- Strengths
- 50mcg + 20mcg
Prescription and consultation requirements for Combimist L Inhaler vary by destination and are determined by the fulfilment partner.
Combimist L Inhaler details
- Conditions
- Bronchospasm · Asthma · Chronic Obstructive Pulmonary Disease
- Alternative names
- levosalbutamol, ipratropium
- Therapeutic class
- Beta-2 Adrenergic Agonist, Anticholinergic Combination
- Pharmacological class
- Bronchodilator Combination
- Contraindications
- hypersensitivity to ipratropium; history of cardiac tachyarrhythmias
- Minor side effects
- dry mouth; cough; headache
- Moderate side effects
- throat irritation; tachycardia; tremor
- Dosage forms
- Inhaler
- Administration route
- Inhalation use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Lupin Ltd
- Onset Time
- 15 minutes
- Duration
- 6–8 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Beta Blockers; Diuretics; Tiotropium
- Age restrictions
- Approved for patients over six years of age.
Serious side effects
paradoxical bronchospasm, requires immediate medical attention; narrow-angle glaucoma flare, requires immediate medical attention
Patient summary
designed to support bronchodilation to manage obstructive airway episodes and alleviate physical breathing distress.
Mechanism of action
Levosalbutamol relaxes airways via beta-2 activation while ipratropium blocks acetylcholine-mediated airway constriction in smooth muscles.
Pregnancy and breastfeeding
TGA Category C: Use if potential benefits outweigh risks. Breastfeeding: Consult a clinician.